BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33977727)

  • 21. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
    Soejima K; Yasuda H; Hirano T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.
    Cheng YL; Chang WK; Yen H; Peng YJ; Chang WC; Chang PY
    Thorac Cancer; 2022 Aug; 13(15):2271-2274. PubMed ID: 35793806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
    Socinski MA; Villaruz LC; Ross J
    Oncologist; 2017 Jan; 22(1):3-11. PubMed ID: 27821794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS; Huang CH; Liu CY; Pavlidis S; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
    Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.
    Lee J; Shim JH; Park WY; Kim HK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2019 Jan; 51(1):408-412. PubMed ID: 29807405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive
    Takeda M; Nakagawa K
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.
    Metro G; Baglivo S; Siggillino A; Ludovini V; Chiari R; Rebonato A; Bellezza G
    Clin Drug Investig; 2018 Oct; 38(10):983-987. PubMed ID: 30151614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.